Showing results (71-80 of 377) with videos related to

Sort By:
Pageof 38
Blood Advances|January 4, 2018
Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML groupPrajwal Boddu, Hagop Kantarjian, Gautam Borthakur, et al.
Leukemia Research|July 23, 2014
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemiaNaval Daver, Aditi Shastri, Tapan Kadia, et al.
Frontiers in Oncology|November 18, 2014
A single case of rosai-dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribineKoji Sasaki, Naveen Pemmaraju, Jason R Westin, et al.
Leukemia Research|September 15, 2014
Clinical significance of microcytosis in patients with primary myelofibrosisPaolo Strati, Naveen Pemmaraju, Zeev Estrov, et al.
Best Practice & Research. Clinical Haematology|March 17, 2009
The coagulopathy of acute promyelocytic leukaemia revisitedEytan Stein, Brandon McMahon, Hau Kwaan, et al.
Mayo Clinic Proceedings|December 18, 2023
Traditional Medicare or Medicare Advantage? The Leukemia and Cancer PerspectiveHagop Kantarjian, Amer M Zeidan, Amir T Fathi, et al.
The Lancet. Haematology|October 23, 2021
Harnessing the benefits of available targeted therapies in acute myeloid leukaemiaHagop Kantarjian, Nicholas J Short, Courtney DiNardo, et al.
Leukemia & Lymphoma|May 25, 2019
Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapyPrajwal Boddu, Preetesh Jain, Gautam Borthakur, et al.
Leukemia & Lymphoma|August 15, 2014
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxideAlireza Eghtedar, Ildefonso Rodriguez, Hagop Kantarjian, et al.
Blood|July 5, 2017
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuationKate J Newberry, Keyur Patel, Lucia Masarova, et al.
Pageof 38